Humacyte’s Return On Capital Employed Insights
Pulled from Benzinga Pro data, Humacyte (NASDAQ:HUMA) posted Q4 earnings of $42.59 million, an increase from Q3 of 234.92%. Sales dropped to $177.00 thousand, a 26.56% decrease between quarters.
Earnings Scheduled For March 29, 2022
Companies Reporting Before The Bell
• 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
How To Attend Humacyte Q4 2021 Earnings Conference Call
Humacyte (NASDAQ:HUMA) will host a conference call at 08:00 AM ET on March 29, 2022, to discuss Q4 2021 earnings results.
How to Attend Humacyte (HUMA) Conference Call
Follow this link to access the live webcast.
Humacyte’s Human Acellular Vessel Shows Long Term Benefit In Hemodialysis Patients
Humacyte Inc (NASDAQ: HUMA)
Humacyte Announces Clinical Case Series Demonstrating Potential Of Human Acellular Vessel To Expand Opportunities For Limb Salvage In Multiple Complex Vascular Reconstruction Scenarios
Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced results from the first series of
Humacyte Posts Preclinical Data Of Small-Diameter Human Acellular Vessel In Bypass Grafting
Humacyte Inc (NASDAQ: HUMA) has announced
Humacyte Announces Results From Preclinical Study Of Small-Diameter Human Acellular Vessel (HAV) In Coronary Artery Bypass Grafting
- HAV remained patent and host-cell remodeling was observed in non-human primate model --
-- Preclinical study represents milestone in the development of small-diameter HAVs for use in cardiac bypass surgery --
--
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year.